Search | Clinical Trials Finder

Conditions: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions: TRX319, Bendamustine; Biological · Drug
Lead sponsor: Tr1X, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more

Conditions: Drooling
Interventions: Botulinum Toxin Type B (Myobloc), Matched placebo to Myobloc; Biological
Lead sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 18
States / cities: Scottsdale, Arizona • Northridge, California • Oxnard, California + 15 more

Conditions: Tourette Syndrome
Interventions: AZD5213 and placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 7
States / cities: Orange, California • St. Petersburg, Florida • Summit, New Jersey + 4 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Psilocybin (0.25mg/kg), Niacin (250mg); Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Myelodysplastic Syndrome
Interventions: CC-1088; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rucaparib, Enzalutamide, Abiraterone; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Nashville, Tennessee

Conditions: Chronic Myelogenous Leukemia
Interventions: TGRX-678; Drug
Lead sponsor: Shenzhen TargetRx Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
Interventions: QR-313, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 4 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 4
States / cities: Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more

Conditions: Malaria, Falciparum
Interventions: FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Neoplasms
Interventions: Screening Platform; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Gainesville, Florida • Waterloo, Iowa • Springfield, Missouri

Conditions: Loneliness
Interventions: Mindfulness Alone (MO) Intervention, Mindfulness + Compassion Intervention (MC); Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alcohol Use Disorder, Hiv, Tobacco Use Disorder
Interventions: Varenicline; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: FSHD - Facioscapulohumeral Muscular Dystrophy
Interventions: ULSC, Placebo; Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 15 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Generalized Anxiety Disorder
Interventions: CYB004, Psychotherapy; Drug · Behavioral
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Hollywood, Florida • Miami Lakes, Florida • Atlanta, Georgia + 3 more

Conditions: Adenylosuccinate Synthase 1 Deficient Myopathy
Interventions: adenylosuccinic acid; Drug
Lead sponsor: Cure ADSSL1; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Becker Muscular Dystrophy
Interventions: (+)-Epicatechin; Drug
Lead sponsor: Epirium Bio Inc.; Industry
Eligibility: 16 Years to 59 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Los Angeles, California • Sacramento, California • St Louis, Missouri

Conditions: Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Interventions: ABT-199, Rituximab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 4
States / cities: La Jolla, California • Chicago, Illinois • New Hyde Park, New York + 1 more

Conditions: Suicide, Psychosis
Interventions: Cognitive Behavioral Suicide Prevention for psychosis (CBSPp), Services as Usual (SAU); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Malignant Neoplasm
Interventions: MK-4884; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: St Louis, Missouri • San Antonio, Texas

Conditions: Multiple Sclerosis
Interventions: Placebo, BMS 188667 (Abatacept); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 10
States / cities: New Haven, Connecticut • Louisville, Kentucky • Worcester, Massachusetts + 7 more

Conditions: Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions: activated recombinant human factor VII, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Cancer, Metastatic Solid Tumor
Interventions: BC3195; Drug
Lead sponsor: Biocity Biopharmaceutics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis
Interventions: PLF with autograft, PLF with NeoFuse; Procedure · Biological
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Opioid Use Disorder, Depressive Disorder
Interventions: Ketamine Hydrochloride; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials

Preliminary Efficacy of a One-Session Mindfulness Telehealth Intervention for Loneliness

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)

A Phase 1b Study of Adenylosuccinic Acid (ASA-001) for Adenylosuccinate Synthase 1 (ADSS1) Deficient Myopathy.

Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer

Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion

Ketamine for OUD and Comorbid Depression (OUDCD)